RxDoctor Payments Data

John Nguyen, PA

Physician Assistant · Redding, CANPI 1558924803

Payments from drug & device makers

$8,150in general payments, 2019–2025

Across 319 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$998
  • Teva Pharmaceuticals USA, Inc.$993
  • Otsuka America Pharmaceutical, Inc.$693
  • Johnson & Johnson$561
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$7,79796%
  • Education$3534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,150 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$21,312
Medicare patients
37
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl13$20,623
TrintellixVortioxetine Hydrobromide12$10,118
VyvanseLisdexamfetamine Dimesylate13$4,456
Atomoxetine Hcl22$2,819
Divalproex Sodium ErDivalproex Sodium43$2,523
Ziprasidone Hcl16$1,552
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$1,279
Bupropion XlBupropion Hcl38$1,061
Aripiprazole28$1,058
Trazodone Hcl57$859
Methylphenidate ErMethylphenidate Hcl11$776
Hydroxyzine Hcl16$606
Risperidone42$591
Venlafaxine Hcl ErVenlafaxine Hcl61$448
Escitalopram Oxalate52$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$18$14,57325 claims
Almatica Pharma LLCSertraline Hcl$55$12322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →